All aboard to hear more about novel targeted therapy combination strategies...
A primer on neoantigens and their importance in cancer research
First-line data for AstraZeneca’s ($AZN) third generation EGFR inhibitor osimertinib (Tagrisso) impresses at the 2016 European Lung Cancer Conference in Geneva.